规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Sulfadoxine is predominantly used in combination with pyrimethamine, commonly known as Fansidar, for the treatment of Plasmodium falciparum. This combination is usually less effective against Plasmodium vivax, probably due to the innate refractoriness of parasites to the sulfadoxine component[2]. Sulfadoxine/pyrimethamine is recommended for intermittent preventative treatment of malaria during pregnancy. During pregnancy, clearance increased 3-fold for sulfadoxine but decreased by 18% for pyrimethamine. Postpartum sulfadoxine clearance decreased gradually over 13 weeks[3]. HIV-infected (HIV(+)) women require more frequent doses of intermittent preventive therapy with SP (Sulfadoxine-pyrimethamine) than do HIV-uninfected (HIV(-)) women. Pregnancy significantly modifies the disposition of SP, whereas HIV status has little influence on pharmacokinetic parameters in pregnant women[4]. SP was associated with a reduced risk of LBW (low birth weight) in HIV-positive women, including those receiving ART, in a low malaria prevalence region[5]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00852371 | Malaria Inter... 展开 >>mittent Preventive Treatment 收起 << | Phase 3 | Completed | - | - |
NCT01449045 | Malaria | Phase 3 | Completed | - | Senegal ... 展开 >> University Cheikh Anta Diop Dakar, Senegal 收起 << |
NCT00941785 | Malaria | Phase 2 Phase 3 | Completed | - | Burkina Faso ... 展开 >> IRSS Bobo-Dioulasso, Burkina Faso, BP545 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.22mL 0.64mL 0.32mL |
16.11mL 3.22mL 1.61mL |
32.22mL 6.44mL 3.22mL |
CAS号 | 2447-57-6 |
分子式 | C12H14N4O4S |
分子量 | 310.33 |
别名 | 磺胺多辛 ;Sulphadoxine;Ro 4-4393;Sulforthomidine;Solfadossina;WR-4873;Sulfadoxin |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:1个月-80°C:12个月 Pure form Keep in dark place,Inert atmosphere,Room temperature |
溶解方案 |
DMSO: 105 mg/mL(338.35 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 |
PO 0.5% CMC-Na 50 mg/mL suspension |